3 unknown, 2 completed, 2 recruiting. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 3, Completed 2, Recruiting 2 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Stuttering: new trials by email Literature Review of Stuttering trials Research Report on Stuttering
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter Psilocybin, Speech therapy - Stuttering | Phase 2 | Recruiting | NYU Langone Health | 25 | 2026-05-07 | 2026-11-10 |
| Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder Lumateperone (ITI-007), Placebo Tablet or Capsule - Stuttering, Adult | Phase 2 | Recruiting | CSTrials Inc. | 24 | 2026-04-18 | 2026-07-29 |
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) Ecopipam, Placebo - Childhood-Onset Fluency Disorder (Stuttering) | Phase 2 | Completed | Emalex Biosciences Inc. | 68 | 2020-10-22 | 2026-09-23 |
| Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Ecopipam 50mg, Ecopipam 100mg - Stuttering, Adult, Childhood-onset Fluency Disorder | Phase 2 / Phase 3 | Unknown | Gerald Maguire, MD | 10 | 2016-09-01 | 2016-10-26 |
| A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering pagoclone, placebo - Stuttering | Phase 2 / Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 321 | 2009-02-01 | 2012-08-28 |
| Follow-up of Children After Stuttering Treatment SMS (Short Message Service) reminders - Stuttering | Phase 2 | Unknown | University of Sydney | 180 | 2009-02-01 | 2010-04-26 |
| Spacing Lidcombe Program Clinic Visits The Lidcombe Program for early stuttering - Stuttering | Phase 2 | Unknown | University of Sydney | 120 | 2008-01-01 | 2008-05-20 |
Childhood-Onset Fluency Disorder (2) · Communication Disorders (2) · Language Disorders (1) · Recurrence (1) · Speech Disorders (1)
Nervous System Diseases (7) · Neurobehavioral Manifestations (7) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Language Disorders (6) · Speech Disorders (6) · Communication Disorders (5) · Mental Disorders (2) · Neurodevelopmental Disorders (2) · Disease Attributes (1) · Pathologic Processes (1)
ecopipam (2) · Capsules (1) · Psilocybin (1) · Speech Therapy (1) · Spermine Synthase (1) · lumateperone (1) · pagoclone (1)
University of Sydney (2) · CSTrials Inc. (1) · Emalex Biosciences Inc. (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Gerald Maguire, MD (1) · NYU Langone Health (1)
United States (5) · Australia (2) · Canada (1)
Atul R Mahableshwarkar, MD, DFAPA (1) · Gerald A Maguire, MD (1) · Mark Onslow (1) · Mark Onslow, PhD (1) · Michael Bogenschutz, MD (1)
PMID 10917410, PMID 12849360, PMID 15026214, PMID 15212606, PMID 15328899, PMID 20075648, PMID 24434529, PMID 28738099, PMID 31369655, PMID 33642973